Therapy-related leukaemia cutis: A review

被引:7
作者
Weinel, Sarah [2 ]
Malone, Janine [2 ]
Jain, Dharamvir [1 ]
Callen, Jeffrey P. [2 ]
机构
[1] Univ Louisville, Dept Med, Div Hematol Oncol, Louisville, KY 40292 USA
[2] Univ Louisville, Dept Med, Div Dermatol, Louisville, KY 40292 USA
关键词
acute myeloid leukaemia; alkylating agents; breast cancer; topoisomerase inhibitors;
D O I
10.1111/j.1440-0960.2008.00466.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Leukaemia cutis following chemotherapy for a malignancy is a multifactorial process that is dependent on the chemotherapeutic agent used, the dosing regimen, and the cumulative dose as well as potential contributing therapies such as radiation and possibly even haematopoeitic support from granulocyte colony stimulating factor. In the right combination and in a patient with a conducive milieu of epigenetic factors, leukaemia can develop as a treatment complication. Leukaemia cutis is the specific infiltration of the skin by leukaemic cells and occurs most commonly when the underlying leukaemia is an acute myeloid leukaemia. Although it is well reviewed in the literature as a result of primary leukaemia, leukaemia cutis has only very rarely been reported in association with therapy-induced leukaemia. This article reviews the factors that contribute to therapy-related leukaemia and the development of leukaemia cutis.
引用
收藏
页码:187 / 190
页数:4
相关论文
共 24 条
[1]   A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis [J].
Agis, H ;
Weltermann, A ;
Fonatsch, C ;
Haas, O ;
Mitterbauer, G ;
Müllauer, L ;
Schreiber, S ;
Schwarzinger, I ;
Juretzka, W ;
Valent, P ;
Jäger, U ;
Lechner, K ;
Geissler, K .
ANNALS OF HEMATOLOGY, 2002, 81 (02) :90-95
[2]  
BAER MR, 1989, CANCER-AM CANCER SOC, V63, P2192, DOI 10.1002/1097-0142(19890601)63:11<2192::AID-CNCR2820631122>3.0.CO
[3]  
2-R
[4]   EXTRAMEDULLARY MYELOID CELL TUMORS IN ACUTE NONLYMPHOCYTIC LEUKEMIA - A CLINICAL REVIEW [J].
BYRD, JC ;
EDENFIELD, WJ ;
SHIELDS, DJ ;
DAWSON, NA .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1800-1816
[5]   RISK OF LEUKEMIA AFTER CHEMOTHERAPY AND RADIATION TREATMENT FOR BREAST-CANCER [J].
CURTIS, RE ;
BOICE, JD ;
STOVALL, M ;
BERNSTEIN, L ;
GREENBERG, RS ;
FLANNERY, JT ;
SCHWARTZ, AG ;
WEYER, P ;
MOLONEY, WC ;
HOOVER, RN .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (26) :1745-1751
[6]   Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center Experience [J].
Diamandidou, E ;
Buzdar, AU ;
Smith, TL ;
Frye, D ;
Witjaksono, M ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2722-2730
[7]   LEUKEMIA IN BREAST-CANCER PATIENTS FOLLOWING ADJUVANT CHEMOTHERAPY OR POSTOPERATIVE RADIATION - THE NSABP EXPERIENCE [J].
FISHER, B ;
ROCKETTE, H ;
FISHER, ER ;
WICKERHAM, DL ;
REDMOND, C ;
BROWN, A .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (12) :1640-1658
[8]   UNRECOGNIZED LEUKEMIA-CUTIS [J].
HAINSWORTH, JD ;
GRECO, FA .
SOUTHERN MEDICAL JOURNAL, 1987, 80 (05) :663-664
[9]   Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies [J].
Kollmannsberger, C ;
Hartmann, JT ;
Kanz, L ;
Bokemeyer, C .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (3-4) :207-214
[10]   Translocation (10;11)(p13;q13) and MLL gene rearrangement in a case of AML (M5a) with aggressive leukemia cutis [J].
Kubonishi, I ;
Seto, M ;
Murata, N ;
Kamioka, M ;
Taguchi, H ;
Miyoshi, I .
CANCER GENETICS AND CYTOGENETICS, 1998, 104 (01) :28-31